JP2014533279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533279A5 JP2014533279A5 JP2014541315A JP2014541315A JP2014533279A5 JP 2014533279 A5 JP2014533279 A5 JP 2014533279A5 JP 2014541315 A JP2014541315 A JP 2014541315A JP 2014541315 A JP2014541315 A JP 2014541315A JP 2014533279 A5 JP2014533279 A5 JP 2014533279A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- antibody
- use according
- cycle
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557815P | 2011-11-09 | 2011-11-09 | |
| US61/557,815 | 2011-11-09 | ||
| US201161569113P | 2011-12-09 | 2011-12-09 | |
| US61/569,113 | 2011-12-09 | ||
| PCT/US2012/064395 WO2013071068A2 (en) | 2011-11-09 | 2012-11-09 | Treatment of hematologic malignancies with an anti-cxcr4 antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533279A JP2014533279A (ja) | 2014-12-11 |
| JP2014533279A5 true JP2014533279A5 (enExample) | 2015-12-24 |
| JP6541350B2 JP6541350B2 (ja) | 2019-07-10 |
Family
ID=47179025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541315A Expired - Fee Related JP6541350B2 (ja) | 2011-11-09 | 2012-11-09 | 抗ｃｘｃｒ４抗体による血液悪性腫瘍の処置 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10428151B2 (enExample) |
| EP (1) | EP2776032B1 (enExample) |
| JP (1) | JP6541350B2 (enExample) |
| KR (1) | KR102024957B1 (enExample) |
| CN (1) | CN104039320B (enExample) |
| AU (1) | AU2012335553B2 (enExample) |
| BR (1) | BR112014011144A2 (enExample) |
| CA (1) | CA2855155A1 (enExample) |
| CY (1) | CY1121331T1 (enExample) |
| DK (1) | DK2776032T3 (enExample) |
| EA (1) | EA026153B1 (enExample) |
| ES (1) | ES2705001T3 (enExample) |
| HR (1) | HRP20182183T1 (enExample) |
| HU (1) | HUE043001T2 (enExample) |
| IL (1) | IL232517B (enExample) |
| LT (1) | LT2776032T (enExample) |
| MX (1) | MX357100B (enExample) |
| PL (1) | PL2776032T3 (enExample) |
| PT (1) | PT2776032T (enExample) |
| RS (1) | RS58102B1 (enExample) |
| SG (1) | SG11201401386XA (enExample) |
| SI (1) | SI2776032T1 (enExample) |
| SM (1) | SMT201900026T1 (enExample) |
| WO (1) | WO2013071068A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007320024B2 (en) * | 2006-10-02 | 2012-11-08 | E. R. Squibb & Sons, L.L.C. | Human antibodies that bind CXCR4 and uses thereof |
| WO2013006443A2 (en) | 2011-07-01 | 2013-01-10 | Dana-Farber Cancer Institute, Inc. | Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma |
| JP2016527303A (ja) * | 2013-08-05 | 2016-09-08 | ケンブリッジ エンタープライズ リミテッド | がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害 |
| EP3044338B1 (en) * | 2013-09-12 | 2021-11-24 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
| US10233248B2 (en) | 2013-11-06 | 2019-03-19 | Bristol-Myers Squibb Company | Treatment of C1013G/CXCR4-associated waldenstroöm's macroglobulinemia with an anti-CXCR4 antibody |
| AU2014360426B2 (en) | 2013-12-06 | 2020-05-07 | Dana-Farber Cancer Institute, Inc. | Methods to distinguish Waldenstrom's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance |
| USRE50030E1 (en) | 2013-12-13 | 2024-07-02 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| KR102775902B1 (ko) | 2013-12-17 | 2025-03-06 | 크링 바이오테라퓨틱스 비.브이. | 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법 |
| WO2015118538A1 (en) * | 2014-02-06 | 2015-08-13 | Yeda Research And Development Co. Ltd. | Anti cd84 antibodies, compositions comprising same and uses thereof |
| KR20160132031A (ko) * | 2014-02-19 | 2016-11-16 | 마이크로콘스탄스 차이나 아이엔씨 | 케모카인 수용체 대항물질 및 그것의 병용 요법 |
| DK3242685T3 (da) * | 2015-01-09 | 2022-07-25 | Adalta Ltd | Cxcr4-bindende molekyler |
| SG10201912035YA (en) | 2015-04-17 | 2020-02-27 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| EA201792522A1 (ru) | 2015-06-12 | 2018-05-31 | Бристол-Майерс Сквибб Компани | Лечение злокачественной опухоли с помощью комбинированной блокады сигнальных путей pd-1 и cxcr4 |
| BR112018000903A2 (pt) | 2015-07-16 | 2018-09-11 | Biokine Therapeutics Ltd. | composições e métodos para o tratamento de câncer |
| ES2907486T3 (es) * | 2015-09-24 | 2022-04-25 | Univ North Carolina Chapel Hill | Métodos y composiciones para reducir metástasis |
| US20180353472A1 (en) * | 2015-11-09 | 2018-12-13 | The General Hospital Corporation D.B.A Massachusetts General Hospital | Unit dose formulations for use as an anti-fugetactic agent |
| ES2830726T3 (es) * | 2016-02-23 | 2021-06-04 | Biolinerx Ltd | Método para seleccionar un régimen de tratamiento para la leucemia mieloide aguda (LMA) |
| CA3019182A1 (en) | 2016-04-29 | 2017-11-02 | Dana-Farber Cancer Institute, Inc. | Hck as a therapeutic target in myd88 mutated diseases |
| CN109890387B (zh) | 2016-05-20 | 2022-06-14 | 拜尔哈文制药股份有限公司 | 谷氨酸调节剂与免疫疗法用以治疗癌症的用途 |
| CA3027296A1 (en) * | 2016-06-16 | 2017-12-21 | Centre National De La Recherche Scientifique | Compounds useful for decreasing interferon level |
| TW201803905A (zh) | 2016-06-20 | 2018-02-01 | 克馬伯有限公司 | 用於免疫腫瘤學之多重專一性抗體 |
| JP2020508697A (ja) * | 2017-01-31 | 2020-03-26 | エム・エス・エム・プロテイン・テクノロジーズ・インコーポレイテッド | 抗ｃｘｃｒ４抗体 |
| SG11201907594TA (en) * | 2017-02-21 | 2019-09-27 | Kura Oncology Inc | Methods of treating cancer with farnesyltransferase inhibitors |
| SG10202110594UA (en) | 2017-03-31 | 2021-11-29 | Bristol Myers Squibb Co | Methods of treating tumor |
| WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | TUMOR TREATMENT METHODS |
| WO2019113456A1 (en) * | 2017-12-08 | 2019-06-13 | The Medical College Of Wisconsin, Inc. | Chemokine variants as immune stimulants |
| KR102693317B1 (ko) * | 2018-03-13 | 2024-08-07 | 푼다시온 파라 라 인베스티가시온 바이오메디카 델 호스피탈 우니베르시타리오 라 파즈 | 암 면역요법을 위한, 활성화되고 확장된 자연 킬러 세포와 조합된 항-cxcr4 항체 |
| US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
| EP3774840A1 (en) | 2018-03-27 | 2021-02-17 | Bristol-Myers Squibb Company | Real-time monitoring of protein concentration using ultraviolet signal |
| CN111971306A (zh) | 2018-03-30 | 2020-11-20 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
| WO2020172658A1 (en) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| WO2020237221A1 (en) | 2019-05-23 | 2020-11-26 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
| JP2023544410A (ja) | 2020-10-05 | 2023-10-23 | ブリストル－マイヤーズ スクイブ カンパニー | タンパク質を濃縮するための方法 |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| US20250188152A1 (en) | 2022-03-09 | 2025-06-12 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
| EP4658310A1 (en) * | 2023-01-30 | 2025-12-10 | Kymab Limited | Antibodies |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| CN119119196B (zh) * | 2024-08-01 | 2025-09-09 | 青岛大学 | 一种基于Motixafortide-喜树碱缀合物及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JP3367581B2 (ja) | 1993-10-14 | 2003-01-14 | 小野薬品工業株式会社 | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞 |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| ATE532861T1 (de) | 2003-09-04 | 2011-11-15 | Medarex Inc | Expressionsvektor |
| CA2597717C (en) | 2005-02-18 | 2014-10-21 | Dana-Farber Cancer Institute | Antibodies against cxcr4 and methods of use thereof |
| US8569280B2 (en) * | 2005-04-25 | 2013-10-29 | Immune Disease Institute | Methods for the treatment of multiple myeloma |
| PT2029155E (pt) * | 2006-02-28 | 2016-06-17 | Pharma Mar Sa | Tratamento melhorado de mieloma múltiplo |
| AU2007320024B2 (en) * | 2006-10-02 | 2012-11-08 | E. R. Squibb & Sons, L.L.C. | Human antibodies that bind CXCR4 and uses thereof |
| FR2915102B1 (fr) | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
| KR20100133012A (ko) * | 2008-05-14 | 2010-12-20 | 일라이 릴리 앤드 캄파니 | 항-ｃｘｃｒ4 항체 |
| EP2352764B1 (en) | 2008-10-14 | 2018-03-28 | Ablynx N.V. | AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY |
| EP2405916B1 (en) * | 2009-03-12 | 2018-02-07 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| US20100298255A1 (en) * | 2009-05-19 | 2010-11-25 | Vivia Biotech S.L. | Methods for providing personalized medicine test ex vivo for hematological neoplasms |
| BR112013003823A2 (pt) | 2010-08-20 | 2016-06-28 | Cerulean Pharma Inc | conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados |
-
2012
- 2012-11-09 EA EA201490957A patent/EA026153B1/ru not_active IP Right Cessation
- 2012-11-09 RS RS20181552A patent/RS58102B1/sr unknown
- 2012-11-09 US US14/356,996 patent/US10428151B2/en active Active
- 2012-11-09 MX MX2014005267A patent/MX357100B/es active IP Right Grant
- 2012-11-09 WO PCT/US2012/064395 patent/WO2013071068A2/en not_active Ceased
- 2012-11-09 CA CA2855155A patent/CA2855155A1/en not_active Abandoned
- 2012-11-09 PT PT12787343T patent/PT2776032T/pt unknown
- 2012-11-09 HU HUE12787343A patent/HUE043001T2/hu unknown
- 2012-11-09 DK DK12787343.8T patent/DK2776032T3/en active
- 2012-11-09 HR HRP20182183TT patent/HRP20182183T1/hr unknown
- 2012-11-09 AU AU2012335553A patent/AU2012335553B2/en not_active Ceased
- 2012-11-09 EP EP12787343.8A patent/EP2776032B1/en active Active
- 2012-11-09 LT LTEP12787343.8T patent/LT2776032T/lt unknown
- 2012-11-09 CN CN201280066551.7A patent/CN104039320B/zh not_active Expired - Fee Related
- 2012-11-09 SM SM20190026T patent/SMT201900026T1/it unknown
- 2012-11-09 JP JP2014541315A patent/JP6541350B2/ja not_active Expired - Fee Related
- 2012-11-09 PL PL12787343T patent/PL2776032T3/pl unknown
- 2012-11-09 ES ES12787343T patent/ES2705001T3/es active Active
- 2012-11-09 SI SI201231459T patent/SI2776032T1/sl unknown
- 2012-11-09 KR KR1020147012396A patent/KR102024957B1/ko not_active Expired - Fee Related
- 2012-11-09 SG SG11201401386XA patent/SG11201401386XA/en unknown
- 2012-11-09 BR BR112014011144A patent/BR112014011144A2/pt not_active Application Discontinuation
-
2014
- 2014-05-08 IL IL232517A patent/IL232517B/en active IP Right Grant
-
2019
- 2019-01-15 CY CY20191100051T patent/CY1121331T1/el unknown
- 2019-10-01 US US16/590,152 patent/US20200231683A1/en not_active Abandoned